2019: State of corneal crosslinking for patients with keratoconus
Stabilization, improvement in corneal curvature measurements seen in many treated cases
Reviewed by Uri S. Soiberman, MD
Keratoconous-a common,
Based on the results of the U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment, the original Dresden protocol entailing epithelial removal followed by application of riboflavin and use of full-fluence UV-A irradiation received FDA approval in 2016 for use in progressive keratoconus and in post-refractive ectasia as well. It’s also used off-label for infectious keratitis.
Unfortunately, disease onset tends to be in early adolescence, and these younger patients are at risk for rapid progression and a lifelong visual disability, noted Uri S. Soiberman, MD, assistant professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.
At the institute,
“Our results at Wilmer are consistent with those of the larger randomized, controlled U.S. trial,” he said. “We see either stabilization or improvement in corneal curvature measurements in most of our treated patients. Treating very rapidly progressive disease remains a challenge, as well as very advanced disease. Early detection is of utmost importance in keratoconus.”
Unfortunately, epi-off CXL is not appropriate for all keratoconus patients.
Patients with very advanced disease and thin corneas will not benefit from the treatment. New approaches are being developed, such as customized treatments, and novel epi-on (transepithelial) procedures.
Disclosures:
Uri S. Soiberman, MD
E: [email protected]
This article was adapted from Dr. Soiberman’s presentation at the 2018 Johns Hopkins Wilmer Eye Institute’s Current Concepts in Ophthalmology meeting in Baltimore. Dr. Soiberman has no financial interests to disclose.
Articles in this issue
over 6 years ago
Valuing power of the lenticleover 6 years ago
CAIRS may eliminate complications from synthetic ring segmentsover 6 years ago
Study: RLE, monovision LASIK results similar in 45-60 age groupover 6 years ago
Making the most of diagnostic technology toolkitover 6 years ago
Optical sector must embrace the telemedicine waveNewsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Articles
- OKYO Pharma details next clinical stage of urcosimod development
September 22nd 2025
- Lions World Vision Institute expands OptiGraft CAIRS service
September 17th 2025
- EyeCon 2025: Sun, sea, and a shared vision for the future of eye care
September 17th 2025
- EyeCool Therapeutics appoints Vance Thompson, MD, to board of directors
September 3rd 2025
- NK Insights: An Interactive Corneal Sensitivity Testing Workshop
August 29th 2025